FDA Law Blog
JULY 22, 2021
Schlanger — Maine and Nevada previously enacted laws requiring drug manufacturers to report information about the pricing of their products. Both states’ new requirements will become effective in October 2021 and should be considered as manufacturers prepare for state drug price transparency reporting in 2022.
My Green Doctor
MAY 3, 2025
operating rooms is regulated by the individual states; changing to multi-dose eyedrops will require administrative and legislative advocacy by eye specialists in every state and country. The product manufacturers and vendors will need to be active partners as well. The use of medications in U.S.
FDA Law Blog
OCTOBER 14, 2024
These procedures are offered to treat a variety of conditions, including Alzheimer’s, arthritis, asthma, cancer, etc., The lowest risk category, which is not subject to any oversight by FDA, includes HCT/Ps removed from an individual that are implanted into the same individual during the “same surgical procedure.” 21 U.S.C. §
Expert insights. Personalized for you.
52 
Let's personalize your content